Form 8-K
8-K — NEUROONE MEDICAL TECHNOLOGIES Corp
Accession: 0001213900-26-106677
Filed: 2026-10-05
Period: 2026-10-05
CIK: 0001500198
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Results of Operations and Financial Condition
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — ea0307577-8k_neuroone.htm (Primary)
EX-99.1 — PRESS RELEASE, DATED OCTOBER 5, 2026 (ea030757701ex99-1.htm)
GRAPHIC (ea030757701_ex99-1img1.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: ea0307577-8k_neuroone.htm · Sequence: 1
false
0001500198
0001500198
2026-10-05
2026-10-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October
5, 2026
NeuroOne Medical Technologies Corporation
(Exact name of registrant as specified in its charter)
Delaware
001-40439
27-0863354
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
7599 Anagram Dr., Eden Prairie, MN 55344
(Address of principal executive offices and zip code)
952-426-1383
(Registrant’s telephone number including area
code)
(Registrant’s former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
NMTC
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 5, 2026, NeuroOne Medical Technologies
Corporation (the “Company”) issued a press release announcing certain preliminary, unaudited financial results for the fiscal
quarter and year ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on
Form 8-K (this “Current Report”) and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information
in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K is being furnished and shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that Section. Furthermore, such information, including Exhibit 99.1 attached hereto, shall not be deemed to be incorporated
by reference in any filing under the Securities Act of 1933, as amended, except as expressly stated by specific reference in such a filing.
Item 8.01 Other Events
Preliminary Results
On October 5, 2026, the Company reported the
following preliminary, unaudited fiscal year 2026 financial and operational results:
●
Achieved annual total revenue of approximately $10.5 million for the year ended September 30, 2026.
●
Achieved quarterly revenue of approximately $3.8 million for the quarter ended September 30, 2026.
Purchase Order
On October 5, 2026, the Company reported
receipt during September 2026 of a purchase order for $4.5 million. Approximately $1.0 million of
the order shipped by September 30, 2026, with shipments of the remaining $3.6 million expected to begin during the first quarter of fiscal
2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated October 5, 2026
104
Cover Page Interactive Data File (embedded with Inline XBRL document).
1
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not
relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding
the Company’s revenue results, financial outlook, product demand, commitments or opportunities, and growth expectations or targets,
as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”,
“forecast”, “estimate,” “may,” “should,” “anticipate” and similar statements
of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. The preliminary,
estimated financial results for the annual fiscal year contained in this Current Report on Form 8-K are subject to the
completion of management’s and the audit committee’s final reviews and our other financial closing procedures and are therefore
subject to change. You should not place undue reliance on such preliminary information and estimates because they may prove to be materially
inaccurate. The preliminary information and estimates have not been compiled or examined by our independent auditors and they are subject
to revision as we prepare our financial statements as of and for the fiscal year ended September 30, 2026, including all disclosures
required by U.S. generally accepted accounting principles. While we believe that such preliminary information and estimates are based
on reasonable assumptions, actual results may vary, and such variations may be material. Our actual future results may be materially
different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue
to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization
or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our
technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties
associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the
risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in
the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities;
that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical
trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights;
and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings
with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and
NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes
available in the future.. These forward-looking statements should not be relied upon as representing the Company’s views as of any
date subsequent to the date of this Current Report on Form 8-K.
2
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: October 5, 2026
By:
/s/ David Rosa
David Rosa
Chief Executive Officer
3
EX-99.1 — PRESS RELEASE, DATED OCTOBER 5, 2026
EX-99.1
Filename: ea030757701ex99-1.htm · Sequence: 2
Exhibit 99.1
NeuroOne
Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Preliminary
Fiscal Q4 2026 Product Revenue of $3.8 Million
Preliminary
Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range
EDEN
PRAIRIE, Minn. – October 5, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or
the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological
disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September
30, 2026, and provided an update on recent product orders.
NeuroOne
expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million, representing year-over-year growth of 38.4%,
compared to approximately $2.7 million in the fourth quarter of fiscal 2025. For the full fiscal year 2026, the Company expects to report
revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its previously announced revenue
guidance range of $9.2 million to $10.5 million.
In
September 2026, NeuroOne secured a $4.5 million product purchase order, the largest in the Company’s history. Approximately
$1.0 million of the order shipped in September 2026, with shipments of the remaining $3.6 million expected to begin during the
first quarter of fiscal 2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules. Following
receipt of this order, total open purchase orders for shipments through the first quarter of fiscal 2027 increased to $5.4 million
as of September 30, 2026. This record purchase order provides greater visibility into anticipated product shipments, cash flow and
revenue opportunities as the Company enters fiscal 2027.
“Momentum
continues to build across our business,” said Dave Rosa, Chief Executive Officer of NeuroOne. “We are happy to report
that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. We enter fiscal 2027 from a position of strength
supported by $5.4 million in open purchase orders and we are also very well positioned with additional growth drivers including the
commercialization of our trigeminal neuralgia system, international market expansion, and the advancement of our drug delivery
platform.”
Complete
financial results for the fourth quarter and full fiscal year 2026 are expected to be announced in December 2026, in conjunction with
the filing of the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission.
The
selected unaudited financial results included in this press release are preliminary and subject to the completion of year-end accounting
and audit procedures and are therefore subject to adjustment. This preliminary financial information is the responsibility of management
and has been prepared in good faith on a basis consistent with prior periods. As a result, prospective investors should exercise caution
in relying on this information and should not draw any inferences regarding the Company’s financial information that is not provided.
This preliminary financial information should not be viewed as a substitute for complete financial statements prepared in accordance
with United States generally accepted accounting principles.
About
NeuroOne
NeuroOne
Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients
suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology
platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for
brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations
and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged
in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information,
visit nmtc1.com.
Forward
Looking Statements
This
press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in
this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are
subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases,
you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,”
“believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,”
“contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of
these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include
statements regarding the fourth quarter and full fiscal year 2026 revenue amounts, international market expansion, and the launch of
our drug delivery program. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution
you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about
which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside
our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether
due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical
and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives
and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our
technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements
or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our
technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions,
including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These
forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update
any forward–looking statements for any reason, even if new information becomes available in the future.
Company Contact:
800-631-4030
ir@nmtc1.com
Investor Relations:
MZ Group - MZ North America
949-491-8235
NMTC@mzgroup.us
GRAPHIC
GRAPHIC
Filename: ea030757701_ex99-1img1.jpg · Sequence: 3
Binary file (10136 bytes)
Download ea030757701_ex99-1img1.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Cover
Oct. 05, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Oct. 05, 2026
Entity File Number
001-40439
Entity Registrant Name
NeuroOne Medical Technologies Corporation
Entity Central Index Key
0001500198
Entity Tax Identification Number
27-0863354
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
7599 Anagram Dr.
Entity Address, City or Town
Eden Prairie
Entity Address, State or Province
MN
Entity Address, Postal Zip Code
55344
City Area Code
952
Local Phone Number
426-1383
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.001 per share
Trading Symbol
NMTC
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration